8 Citations (Scopus)

Abstract

Introduction: High-dose chemotherapy and autologous stem cell transplantation (ASCT) improve survival in follicular lymphoma; however, relapse remains the most common cause of death. The lower risk of relapse with allogeneic SCT (alloSCT) is offset by a high transplant-related mortality (TRM).Areas Covered: English articles indexed in the MEDLINE database were reviewed to discuss the role of graft purging, rituximab maintenance after ASCT, reduced-intensity conditioning (RIC) alloSCT, T-cell depletion, donor lymphocyte infusion (DLI) and alternate donor sources.Expert Opinion: Optimal salvage consolidation strategy may utilize ASCT following non-total body irradiation-based conditioning regimen in second remission. Rituximab maintenance after ASCT may improve molecular remission but is not yet shown to improve overall survival. RIC alloSCT permits its use in older and less-fit patients. Studies with T-cell depleted graft failed to reduce TRM despite a decline in graft-versus-host disease; however, these studies did demonstrate a therapeutic role of DLI in post-transplant relapses. In recent years, haploidentical and umbilical cord blood donors have emerged as alternative donor sources, with outcomes comparable to matched unrelated donor SCT. In the future, incorporation of novel therapeutic agents, improved risk-adapted treatment strategies, and advancement of transplant techniques may provide a better chance of survival.

Original languageEnglish (US)
Pages (from-to)57-66
Number of pages10
JournalExpert Opinion on Biological Therapy
Volume16
Issue number1
DOIs
StatePublished - Jan 2 2016

Fingerprint

Transplants
Follicular Lymphoma
Hematopoietic Stem Cell Transplantation
Stem cells
Grafts
Stem Cell Transplantation
T-cells
Lymphocytes
Tissue Donors
Purging
Recurrence
Salvaging
Chemotherapy
Survival
Maintenance
Consolidation
Lymphocyte Depletion
T-Lymphocytes
Unrelated Donors
Blood

Keywords

  • allogeneic hematopoietic stem cell transplantation
  • autologous hematopoietic stem cell transplantation
  • follicular lymphoma
  • survival

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

@article{5b72c30df47b4351bb4dc219767e9632,
title = "Autologous and allogeneic hematopoietic stem cell transplantation in follicular lymphoma",
abstract = "Introduction: High-dose chemotherapy and autologous stem cell transplantation (ASCT) improve survival in follicular lymphoma; however, relapse remains the most common cause of death. The lower risk of relapse with allogeneic SCT (alloSCT) is offset by a high transplant-related mortality (TRM).Areas Covered: English articles indexed in the MEDLINE database were reviewed to discuss the role of graft purging, rituximab maintenance after ASCT, reduced-intensity conditioning (RIC) alloSCT, T-cell depletion, donor lymphocyte infusion (DLI) and alternate donor sources.Expert Opinion: Optimal salvage consolidation strategy may utilize ASCT following non-total body irradiation-based conditioning regimen in second remission. Rituximab maintenance after ASCT may improve molecular remission but is not yet shown to improve overall survival. RIC alloSCT permits its use in older and less-fit patients. Studies with T-cell depleted graft failed to reduce TRM despite a decline in graft-versus-host disease; however, these studies did demonstrate a therapeutic role of DLI in post-transplant relapses. In recent years, haploidentical and umbilical cord blood donors have emerged as alternative donor sources, with outcomes comparable to matched unrelated donor SCT. In the future, incorporation of novel therapeutic agents, improved risk-adapted treatment strategies, and advancement of transplant techniques may provide a better chance of survival.",
keywords = "allogeneic hematopoietic stem cell transplantation, autologous hematopoietic stem cell transplantation, follicular lymphoma, survival",
author = "Bhatt, {Vijaya R} and Armitage, {James Olen}",
year = "2016",
month = "1",
day = "2",
doi = "10.1517/14712598.2016.1096341",
language = "English (US)",
volume = "16",
pages = "57--66",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Autologous and allogeneic hematopoietic stem cell transplantation in follicular lymphoma

AU - Bhatt, Vijaya R

AU - Armitage, James Olen

PY - 2016/1/2

Y1 - 2016/1/2

N2 - Introduction: High-dose chemotherapy and autologous stem cell transplantation (ASCT) improve survival in follicular lymphoma; however, relapse remains the most common cause of death. The lower risk of relapse with allogeneic SCT (alloSCT) is offset by a high transplant-related mortality (TRM).Areas Covered: English articles indexed in the MEDLINE database were reviewed to discuss the role of graft purging, rituximab maintenance after ASCT, reduced-intensity conditioning (RIC) alloSCT, T-cell depletion, donor lymphocyte infusion (DLI) and alternate donor sources.Expert Opinion: Optimal salvage consolidation strategy may utilize ASCT following non-total body irradiation-based conditioning regimen in second remission. Rituximab maintenance after ASCT may improve molecular remission but is not yet shown to improve overall survival. RIC alloSCT permits its use in older and less-fit patients. Studies with T-cell depleted graft failed to reduce TRM despite a decline in graft-versus-host disease; however, these studies did demonstrate a therapeutic role of DLI in post-transplant relapses. In recent years, haploidentical and umbilical cord blood donors have emerged as alternative donor sources, with outcomes comparable to matched unrelated donor SCT. In the future, incorporation of novel therapeutic agents, improved risk-adapted treatment strategies, and advancement of transplant techniques may provide a better chance of survival.

AB - Introduction: High-dose chemotherapy and autologous stem cell transplantation (ASCT) improve survival in follicular lymphoma; however, relapse remains the most common cause of death. The lower risk of relapse with allogeneic SCT (alloSCT) is offset by a high transplant-related mortality (TRM).Areas Covered: English articles indexed in the MEDLINE database were reviewed to discuss the role of graft purging, rituximab maintenance after ASCT, reduced-intensity conditioning (RIC) alloSCT, T-cell depletion, donor lymphocyte infusion (DLI) and alternate donor sources.Expert Opinion: Optimal salvage consolidation strategy may utilize ASCT following non-total body irradiation-based conditioning regimen in second remission. Rituximab maintenance after ASCT may improve molecular remission but is not yet shown to improve overall survival. RIC alloSCT permits its use in older and less-fit patients. Studies with T-cell depleted graft failed to reduce TRM despite a decline in graft-versus-host disease; however, these studies did demonstrate a therapeutic role of DLI in post-transplant relapses. In recent years, haploidentical and umbilical cord blood donors have emerged as alternative donor sources, with outcomes comparable to matched unrelated donor SCT. In the future, incorporation of novel therapeutic agents, improved risk-adapted treatment strategies, and advancement of transplant techniques may provide a better chance of survival.

KW - allogeneic hematopoietic stem cell transplantation

KW - autologous hematopoietic stem cell transplantation

KW - follicular lymphoma

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84955632500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955632500&partnerID=8YFLogxK

U2 - 10.1517/14712598.2016.1096341

DO - 10.1517/14712598.2016.1096341

M3 - Article

VL - 16

SP - 57

EP - 66

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 1

ER -